Cost-Effectiveness Analysis of Antihypertensive Combination Treatment in Chronic Kidney Disease Outpatients with Hypertension

Ingenida Hadning; Radhwa Fauztina; Fajar A. Mustofa

doi:10.24198/ijpst.v12s1.57946

Cost-Effectiveness Analysis of Antihypertensive Combination Treatment in Chronic Kidney Disease Outpatients with Hypertension

Ingenida Hadning, Radhwa Fauztina, Fajar A. Mustofa

Abstrak

The expense of managing CKD patients ranks second highest behind cardiovascular illness, with hypertension being the primary contributor to renal impairment. Maximizing the efficiency of therapeutic expenditures is essential. This study is to evaluate the cost-effectiveness of the combination of amlodipine 10 mg - candesartan 16 mg compared to the combination of candesartan 16 mg - furosemide 40 mg in patients with chronic kidney disease and hypertension. The research employed a non-experimental observational cohort design. The study was performed at both a private and a governmental hospital in Yogyakarta, Indonesia. Data were gathered retroactively using complete sampling. The inclusion criteria comprised outpatients with CKD-hypertension from January 2019 to October 2022, aged 18 years or older, who were undergoing combination therapy. The efficacy of therapy was evaluated by determining the number of samples achieving therapeutic objectives after 2 to 4 weeks. The mean expenditure was derived from monthly antihypertensive costs. The analysis of cost-effectiveness employed the Average Cost-Effectiveness Ratio (ACER) and the Incremental Cost-Effectiveness Ratio (ICER). The study comprised 50 samples, with 51% male participants and 66% aged 60 or older. Amlodipine and candesartan demonstrated superior efficacy (77%) and a reduced average cost of 101,095 IDR. The ACER for amlodipine and candesartan was 1,306 IDR, whereas for furosemide and candesartan it was 1,571 IDR. The amalgamation of amlodipine and candesartan is more economically advantageous than furosemide and candesartan.

Kata Kunci

amlodipine; candesartan; chronic kidney disease; cost-effectiveness analysis; furosemide; hypertension

Teks Lengkap:

PDF (English)

Referensi

Tuloli TS, Madania M, Mustapa MA, Tuli EP. Evaluasi Penggunaan Obat pada Pasien Gagal Ginjal Kronik yang Menjalani Hemodialisis di RSUD Toto Kabila Periode 2017-2018. Parapemikir: Jurnal Ilmiah Farmasi. 2019;8(2):25.

KEMENKES RI. INFODATIN Situasi Penyakit Ginjal Kronis. Jakarta; 2017.

KEMENKES RI. Riset Kesehatan Dasar. Jakarta; 2018.

Salvador-González B, Mestre-Ferrer J, Soler-Vila M, Pascual-Benito L, Alonso-Bes E, Cunillera-Puértolas O. Chronic kidney disease in hypertensive subjects ≥60 years treated in Primary Care. Nefrologia: publicacion oficial de la Sociedad Espanola Nefrologia. 2017;37(4):406–14.

Muhadi M. JNC 8: Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa. Cermin Dunia Kedokteran. 2016;43(1):54–9.

Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International. 2021;100(4):S1–276.

Lestari EFA, Susilowati S, Hermawatiningsih OD. Evaluasi Efektivitas Antihipertensi pada Pasien Hipertensi dengan Gagal Ginjal Kronis di Rawat Inap RSUD Kota Madiun. Duta Pharma Journal. 2021;1(2):25–31.

Susanto CE. Biaya Berobat Ginjal Triliunan [Internet]; 2016. [cited in January 2022]. Available from: http://www.mediaindonesia.com/news/read/33493/biaya-berobat-ginjal-triliunan/2016-03-11.

Hadning I, Permatasari I, Suwandi MA, Negeriana RP, Purbaningtyas A, Viviandhari D. Cost effectiveness analysis of antihypertensive captopril and amlodipine in patients with primary hipertension. AIP Conference Proceedings. 2024;3155(1).

Muchtar NR, Tjitrosantoso H, Bodhi W. Studi Penggunaan Obat Antihipertensi pada Pasien Gagal Ginjal Kronik yang Menjalani Perwatan di RSUD Prof. Dr. R. Kandou Manado Periode Juli 2013-2014. Pharmacon. 2015;4(3): 22–8.

Baroroh F, Sari A. Analisis Efektivitas Biaya Pengobatan Kombinasi Candesartan-Amlodipin Dibandingkan dengan Kombinasi Candesartan-Diltiazem pada Pasien Hipertensi Rawat Jalan. Pharmacy: Jurnal Farmasi Indonesia. 2017;14(02):188–98.

Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334–57.

Rizky FA, Andina M. Karakteristik Penderita Hipertensi Dengan Gagal Ginjal Kronik Di Instalasi Penyakit Dalam Rumah Sakit Umum Haji Medan Tahun 2015. Jurnal Ibnu Sina Biomedika. 2017;1(1):87-96.

Putri SD, Apen A, Garina LA. Karakteristik Penderita Gagal Ginjal Kronis yang Dilakukan Hemodialisis di RSUD Al-Ihsan Tahun 2014. Bandung: Universitas Islam Bandung Repository. 2014;1(2): 570–7.

Nurhidayati L. Hubungan Dukungan Keluarga Dengan Kualitas Hidup Pada Pasien Gagal Ginjal Kronis Yang Menjalani Terapi Hemodialisa Di RS PKU Muhammadiyah Yogyakarta. Yogyakarta: Sekolah Tinggi Ilmu Kesehatan ’Aisyiyah. 2014.

Hadning I, Hendrawan H, Rahayu WK. Cost of illness of chronic kidney disease patients with hemodialysis in Yogyakarta Indonesia. AIP Conference Proceedings. 2024;3155(1).

Azziz F, Witjaksono J, Rasjidi I. Panduan pelayanan medik: Model interdisiplin penatalaksaan kanker serviks dengan gangguan ginjal [Internet]; 2008 [Jakarta: EGC]. Available from: http://uilis.unsyiah.ac.id/uilis/index.php?p=show_detail&id=36699

Yulanda G, Lisiswanti R. Penatalaksanaan hipertensi primer. Jurnal Majority. 2017;6(1):28-33.

Wulandari T. Pola Penggunaan Kombinasi Dua Obat Antihipertensi pada Pasien Hipertensi. Jurnal Ilmu Kesehatan. 2019;10(1):77–82.

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2019;74(1):120–31.

Juwita DA, Almahdy, Wati YM. Perbandingan Efektivitas Penggunaan Kombinasi 2 Obat Antihipertensi Pada Pasien Hipertensi di Poliklinik Penyakit Dalam RSUP Dr. M. DJAMIL Padang. 2019.

DOI: https://doi.org/10.24198/ijpst.v12s1.57946